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Abstract
Background: Chloroquine (CQ), the worldwide used anti-malarial drug, has recently being focused as a potential
anti-cancer agent as well as a chemosensitizer when used in combination with anti-cancer drugs. It has been
shown to inhibit cell growth and/or to induce cell death in various types of cancer. 5-Fluorouracil (5-FU) is the
chemotherapeutic agent of first choice in colorectal cancer, but in most cases, resistance to 5-FU develops through
various mechanisms. Here, we focused on the combination of CQ as a mechanism to potentiate the inhibitory
effect of 5-FU on human colon cancer cells.
Methods: HT-29 cells were treated with CQ and/or 5-FU, and their proliferative ability, apoptosis and autophagy
induction effects, and the affection of the cell cycle were evaluated. The proliferative ability of HT-29 was analyzed
by the MTS assay. Apoptosis was quantified by flow-cytometry after double-staining of the cells with AnnexinV/PI.
The cell cycle was evaluated by flow-cytometry after staining of cells with PI. Autophagy was quantified by flow-
cytometry and Western blot analysis. Finally, to evaluate the fate of the cells treated with CQ and/or 5-FU, the
colony formation assay was performed.
Results: 5-FU inhibited the proliferative activity of HT-29 cells, which was mostly dependent on the arrest of the
cells to the G0/G1-phase but also partially on apoptosis induction, and the effect was potentiated by CQ pre-
treatment. The potentiation of the inhibitory effect of 5-FU by CQ was dependent on the increase of p21
Cip1 and
p27
Kip1 and the decrease of CDK2. Since CQ is reported to inhibit autophagy, the catabolic process necessary for
cell survival under conditions of cell starvation or stress, which is induced by cancer cells as a protective
mechanism against chemotherapeutic agents, we also analyzed the induction of autophagy in HT-29. HT-29
induced autophagy in response to 5-FU, and CQ inhibited this induction, a possible mechanism of the potentiation
of the anti-cancer effect of 5-FU.
Conclusion: Our findings suggest that the combination therapy with CQ should be a novel therapeutic modality
to improve efficacy of 5-FU-based chemotherapy, possibly by inhibiting autophagy-dependent resistance to
chemotherapy.
Background
Colorectal cancer is a leading cause of cancer-related
death in developed countries [1]. Surgical resection, fol-
lowed by adjuvant chemo or radiotherapy, remains the
only established curative treatment for colon cancer, but
this treatment is often unsatisfactory in case the patient
present with the disease in an advanced stage or metas-
tasis develops after attempted curative resection.
5-Fluorouracil (5-FU) is the chemotherapeutic agent of
first choice in the treatment of patients with colorectal
cancer. Intracellular metabolites of 5-FU can exert cyto-
toxic effects via inhibition of thymidylate synthetase, or
through incorporation into RNA and DNA, events that
ultimately activate apoptosis [2]. The dose increment of
systemic administration of 5-FU would generate unac-
ceptable levels of toxicity to normal cells, especially of
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severe adverse effects. Therefore, many attempts have
been made to enhance its therapeutic effectiveness,
simultaneously reducing its toxicity. However, presently,
the ideal chemotherapeutic agent or the best combina-
tion of agents, which should cause strong cytotoxicity
against cancer cells, with minimal effect on normal cells,
has not yet been developed.
Chloroquine diphosphate (CQ), a worldwide used
anti-malarial drug, has recently been focused due to its
potential biological effects on cancer cells, such as the
inhibition of cell growth and/or induction of cell death
in human lung cancer A549 cells, glioma cells, human
breast cancer cells, and mouse colon cancer CT26 cells,
resulting in anti-cancer effects [3-7]. And CQ has been
shown to potentiate the inhibitory effect of GX15-070, a
novel proapoptotic anti-tumor agent that inhibit anti-
apoptotic Bcl-2 proteins, on the growth of esophageal
cancer cells [8]. Additionally, CQ has been shown to
inhibit the antitumor effect of tephrosin, a natural rote-
noid that induces internalization of EGFR and ErbB2,
with consequent degradation of these receptors, on
colon cancer cells. This effect was dependent on the
blocking of the degradation of the receptors internalized
into vesicles [9].
In addition to its anti-cancer effects, CQ is a well-
known lysosomotropic agent [10,11]. The lysosomotro-
pic properties of CQ are probably responsible for many
of the biological effects of this drug. Recently, accumu-
lating lines of evidence suggest that, through its lysoso-
motrophic effect, CQ can effectively sensitize cancer
cells to the cell-killing effects of ionizing radiation and
chemotherapeutic agents and, therefore, its use as an
effective sensitizer for the improvement of the effect of
conventional cancer therapies is a promising new thera-
peutic strategy [12]. Hu et al have demonstrated the
effectiveness of CQ as a cancer-specific chemosensitizer
in combination with Akt inhibitors [13].
The cancer-specific chemosensitizer effect of CQ may
be partly dependent on its ability to inhibit autophagy
[10-12]. It was reported to specifically inhibit autophagy
in a mechanism distinct from other autophagy inhibi-
tors, such as 3-methyladenine (3-MA). Whereas 3-MA
inhibits autophagy in its early phase, consequently
resulting in inhibition of the formation of acidic vesicu-
lar organelles (AVOs), which consist predominantly of
autophagosomes and autolysosomes, CQ inhibits autop-
hagy in its late phase, i.e., after AVOs have been formed
in the cytoplasm of the cells and, therefore, CQ-treated
cells show a typical feature of AVOs accumulation in
the cytoplasm [11]. Inhibition of autophagy, therefore, is
a promising new strategy to improve cancer treatment.
In a previous study, inhibition of autophagy with 3-MA
in colon cancer cell lines exposed to 5-FU resulted in
reduced cell survival [14]. And 3-MA was shown to
enhance 5-FU-induced apoptosis in colon cancer cells,
in vitro and in vivo suggestive that autophagy might
play a role as a self-defense mechanism in 5-FU-treated
colon cancer cells [15,16]. We have also demonstrated
that inhibition of autophagy in colon cancer cells with
3-MA potentiated the proapoptotic effect of sulfora-
phane, a kind of isothiocyanate, with strong pro-apopto-
tic effects against cancer cells as well as endothelial cells
[17]. Taking these facts, CQ, through its lysosomotropic
properties as well as the autophagy inhibition ability,
m a yb eap r o m i s i n ga g e n tt ob eu s e di nc o m b i n a t i o n
with chemotherapeutic agents for the improvement of
clinical results.
Since its introduction into clinical practice in 1947 for
the prophylaxis treatment of malaria (Plasmodium vivax,
ovale and malariae), CQ still remains the drug of choice
for malaria chemotherapy, because of its high effective-
ness and well tolerance by humans [12]. In addition, CQ
is widely used as an anti-inflammatory drug for the
treatment of rheumatoid arthritis, lupus erythematosus
and amoebic hepatitis. Therefore, the great advantage of
CQ over other inhibitors of autophagy, including 3-MA,
is the feasibility of its introduction to the clinical set-
tings of cancer therapy without need of animal or
phase-one studies. Since CQ and 3-MA inhibit different
steps of the autophagic process, there is need to confirm
the effectiveness of CQ in potentiating the anti-cancer
effect of 5-FU against colon cancer cells, in a similar
mechanism as 3-MA.
In the present study, therefore, we aimed to investi-
gate the effect of the combination therapy of 5-FU with
CQ on human colorectal cancer cells, namely HT-29.
Cells were treated with CQ or/and 5-FU, and their pro-
liferative ability, induction of apoptosis, and the changes
of cell cycle were evaluated. In addition, the ability of
HT-29 to induce autophagy in response to 5-FU, and
the affection of autophagy by CQ were analyzed. Our
results demonstrated that treatment with CQ, at a rela-
tively low concentration for a short period of time,
although without a direct inhibitory effect on HT-29
cell proliferation and cell growth, potentiated the inhibi-
tory effect of 5-FU on the proliferative activity, which
was dependent on the cell cycle arrest in the G0/G1
phase.
Methods
Cells and Reagents
The human colorectal cancer cell line, HT-29, obtained
from the Japanese Cancer Research Resource Bank, was
used. Cells were cultured in RPMI-1640 medium sup-
plemented with 5% fetal calf serum, 1% antibiotics/anti-
mycotic (complete medium) and incubated in a 5% CO2
incubator at 37°C. 5-fluorouracil (FU), Chloroquine
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1640 medium were purchased from Sigma-Aldrich (St
Louis, MO, USA). Fetal calf sera, and antibiotics/antimy-
cotics were from Gibco BRL (Grand Island, NY, USA).
Calcium and magnesium-free phosphate-buffered saline
(PBS (-)) was from Wako Pure Chemical Industries, Ltd
(Osaka, Japan). Acridine orange and trypan blue were
from Sigma-Aldrich Japan (Tokyo, Japan).
5-fluorouracil and Chloroquine treatment
Prior to each treatment, HT-29 cells were grown until
they reached about 30-50% subconfluence. Then, to test
the independent effects of 5-FU and CQ on HT-29, the
cells were treated with 5-FU at 0.01, 0.1, 1, 10, 100, or
1000 μM for 24, 48, and 72 h, or with CQ at 0.1, 1, 10,
100, or 1000 μM CQ for 12, and 24 h, in an attempt to
determine the dose of CQ that effectively inhibited
autophagy without affecting the proliferative activity of
HT-29. Additionally, the dose of 5-FU and the treat-
ment time necessary for the 50% inhibition (CI50) of
the proliferative activity of HT-29 was determined.
To assess the effects of the co-treatment with 5-FU
and CQ, the cells were pre-treated with CQ at the dose
of 80 μM for 12 h, and after washing with PBS, cells
were treated with the determined doses of 5-FU for
another 48 h. The dose of CQ was set at 80 μM because
it was the dose that mostly induced AVOs formation,
the marker of autophagy, with minimal inhibitory effect
on HT-29 cells.
In the subsequent experiments, cells were pre-treated
with CQ (80 μM) for 12 h, followed by 5-FU (5 μM) for
another 24-48 h.
Cell proliferation assay and Cell growth assessment
In the preliminary experiment, cells were treated with
either CQ or 5-FU at the various concentrations for the
different periods of time, and in the subsequent experi-
ments, by CQ plus 5-FU, as above described. The MTS
assay was used for the assessment of cell proliferation,
and cell growth was assessed by counting live cells after
staining with trypan blue. Cell Titer 96TM aqueous
nonradioactive cell proliferation assay (Promega, Madi-
son, WI, USA) was used according to the manufac-
turer’s recommendation. The assay consisted of
tetrazolium compound (inner salt, MTS) and an elec-
tron coupling reagent, phenazine methosulfate (PMS).
MTS is converted by the dehydrogenase enzymes into a
formazan, which is found in metabolically active cells
and is soluble in tissue culture medium. The absorbance
of the formazan at 490 nm was measured directly in a
96-well plate using a microtiter plate reader (Beckton
Dickinson). Dehydrogenase enzymes found in metaboli-
cally active cells accomplish the conversion of MTS into
the aqueous-soluble formazan. The quantity of formazan
product, and thus the amount of 490 nm absorbance, is
directly proportional to the number of living cells in the
culture. The treated and untreated control cells were
cultured in 96-well flat-bottomed plates at a density of 5
×1 0
3 cells per well in 100 μl complete medium, at 37°C
in an atmosphere of 5% CO2.T h e n ,2 0μlo ft h eM T S
solution was added to each well and incubated at 37°C
for 3-4 hours. All experiments were performed in tripli-
cate wells, and the proliferation of HT-29 cells was cal-
culated as the ratio of each experimental condition to
the control one (untreated cells).
Detection of Acidic vesicular organelles (AVOs)
For the analysis of autophagy induction, acidic vesicular
organelles (AVOs), which consist predominantly of
autophagosomes, and autolysosomes, were quantified by
flow cytometry after staining of cells with acridine
orange (AO). AO is a fluorescent weak base that accu-
mulates in acidic spaces and fluoresce bright red. The
intensity of the red fluorescence is proportional to the
degree of acidity. Thus, AO fluorescence intensity,
which represents AVOs formation, can be quantified by
flow-cytometry. HT-29 cells were prepared and treated
as described, and the cells were collected in FACS tubes
(BD Biosciences Discovery Labware, MA, USA) and
resuspended in PBS (-). The cell suspension was stained
with AO (5 μg/ml) for 15 min at room temperature.
The cells were washed twice with PBS (-), resuspended
in PBS and analyzed on a flow-cytometer using the Cell-
Quest software, and examined under a fluorescence
microscope at 40 × objective lens magnification. The
experiment was performed three times with essentially
the same results.
Immunocytochemistry for LC3 localization
HT-29 cells were prepared and treated as described,
washed with PBS (-) and fixed with 4% paraformalde-
hyde at 4°C overnight. Subsequently, the cells were per-
meabilized with 0.1% Tween-20 for 15 minutes at room
temperature, and blocked with 0.2% bovine serum albu-
min (BSA) for 1 hour at room temperature. The cells
were treated with anti-LC3 antibody (MBL, Nagoya,
Japan) for 1 hour at room temperature. Cells were then
washed with BSA buffer and incubated with 2 μg/mL
Alexa Fluor 488-conjugated goat anti-rabbit antibody
(Eugene, OR, USA) for 1 hour at room temperature and
examined under a fluorescence microscope at 40 ×
objective lens magnification.
Detection of apoptosis by flow-cytometry
HT-29 cells were prepared and treated as described, and
then stained with fluorescein isothiocyanate (FITC)-con-
jugated annexin V and propidium iodide (PI) for 5 min-
utes at room temperature according to manufacturer’s
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BD Pharmingen, CA, USA). The population of annexin
V
-PI
- viable cells and annexin V
+ apoptotic cells was
evaluated by flow-cytometry, and the later were consid-
ered apoptotic cells. Data were collected in a FACS Cali-
bur (Becton-Dickinson, Mountain View, Calif) and
analyzed by using the Cell Quest software (Becton-Dick-
inson). The experiment was performed three times, and
the ratio of apoptotic cells was expressed as mean ± SD.
Analysis of the cell cycle by flow-cytometry
HT-29 cells were prepared and treated as described, and
then the percentage of cells in each phase of the cell
cycle was analyzed by flow-cytometry, using the Cycle
TEST PLUS DNA Reagent Kit (BD Pharmingen, San
Jose, CA, USA), which is based on the measurement of
the DNA content of nuclei labeled with propidium
iodide (PI), according to manufacturer’s instructions.
Treated cells were trypsynized (250 μL of trypsin buffer)
for 10 min at room temperature, and then trypsin inhi-
bitor (200 μL) and RNase buffer were added and
a l l o w e dt or e a c tf o r1 0m i na tr o o mt e m p e r a t u r e .
Finally, propidium iodide stain solution (200 μL) was
added and incubated for 10 min in the dark, on ice.
Samples were immediately analyzed in the flow-cyt-
ometer (Becton-Dickinson, Mountain View, Calif), and
the obtained results analyzed by the Cell Quest software
(Becton-Dickinson). The experiment was performed
three times, and the ratio of cells in the G0/G1, intra-S,
and G2/M phases were expressed as mean ± SD.
Colony forming assay
HT-29 cells, suspended in fresh culture medium, were
plated 200 cells/well onto 24-well microtiter plates.
After 24 hours of culture, to allow cells to attach, cells
were treated with CQ and/or 5-FU, respectively, at 80
or 5 μM for 12 or 48 hours. Then, cells were washed
with PBS (-), and fed with fresh culture medium, with-
out5-FU, and allowed to grow for 11 days in normal
culture conditions (37°C, 5%CO2). During the 11 days of
culture, the colonies that contained 50 or more cells
were counted under light microscope. For each experi-
mental condition, colonies from 3 different wells were
counted. The proliferative ability of HT-29 cells was cal-
culated as the ratio of the experimental condition to the
control one at day 5 (untreated cells).
Western Blot Analysis
Cells were treated as above described, and. after 3 times
washing with PBS(-), cells were harvested by scraping
the culture dishes with a cell scraper and subsequently
lysed with 0.5 ml of Tris-saline (50 mM Tris-HCl (pH
7.6), 150 mM sodium chloride) containing various pro-
tease inhibitors (1 mM EGTA, 0.1 mM diisopropyl
fluorophosphates, 0.5 mM phenylmethyl-sulphonyl
fluoride, 1 mg/ml Na-r-tosyl-L-lysine chloromethyl
ketone, 1 mg/ml anti-pain, 0.1 mg/ml pepstain, 1 mg/ml
of leupeptin) and 1% Triton-X for 1 hour in cold room.
After centrifuged at 15,000 rpm for 5 minutes, the clear
supernatant was collected and used as the cell protein
extract. Protein concentration was determined using the
BCA Protein Assay Kit (Pierce Biomedical Co, Rockford,
IL). Cell lysates were separated on a 15% Ready Gel J
SDS-PAGE (Bio-Rad, Hercules, CA, USA) for Hybond
ECL nitrocellulose membrane blotting (Amersham Phar-
macia Biotech, Buckinghamshire, England). The blotted
membranes were blocked with 5% skim milk for 1 hour
and were incubated with each primary antibody over-
night at 4°C. The following primary antibodies were
used: anti-Cdk2, -Cdk4, -Cdk6, -b-actin were purchased
from Santa-Cruz Biotechnology (Santa Cruz, CA, USA).
LC3, cyclinD1, cyclin E were from Medical Biological
Laboratories CO (Nagoya, Japan). p27
Kip1,p 2 1
Cip1 were
purchased from Cell Signaling Technology (Beverley,
MA, USA). Following the primary antibody incubation,
the blots were washed and incubated with 1:10000 dilu-
tion of biotinylated anti-rabbit IgG (Vector Laboratories,
Inc, Burlingame, CA, USA) or biotinylated anti-mouse
IgG (Vector Laboratories, Inc, Burlingame, CA, USA), as
appropriate. The immunoreactive bands were visualized
by enhanced chemiluminescence using the ECL detec-
tion system (Amersham Pharmacia Biotech, Buckin-
ghamshire, England). The density of each band was
measured using Image J software (open source Image J
software available at http://rsb.info.nih.gov/ij/).
Statistical analysis
All of experiments were repeated at least three times.
Statistical significance of the differences was evaluated
by the unpaired, 2-tailed Student’s t-test, and an associa-
tion was considered significant when the exact signifi-
cant level of the test was P < 0.05.
Results
Effect of 5-FU and CQ on the proliferative activity of
HT-29 cells
5-FU, at doses lower than 0.01 μM, had almost no inhi-
bitory effect on HT-29 cells, after 24, 48 or 72 hr treat-
ment. At the concentrations over 0.1 μM, 5-FU
inhibited the proliferation of HT-29 cells in time- and
dose-dependent manner (Fig. 1A). On the other hand,
CQ at doses lower than 100 μM in a 12 h-treatment, or
at 10 μM in a 24 h-treatment, had minimal inhibitory
effect on HT-29 cells (Fig. 1B). Based on these results,
t h ed o s eo f8 0μM of CQ in a 12 h-treatment, which
had no inhibitory effect on HT-29 cells, and that of
5 μM of 5-FU for 48-72 h, which had around 50% inhi-
bitory effect, were chosen for the further experiments.
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growth inhibition
Treatment with 5-FU at 5 μM for 48 hours resulted in
inhibition of the proliferative activity of HT-29 to
approximately 67% of untreated control cells. Pre-treat-
ment of cells with CQ at 80 μM for 12 h prior to expo-
sure to 5-FU enhanced the inhibitory effect, the
proliferative activity decreasing to approximately 33% of
the control (Fig. 2A). Then, cell viability was assessed by
the trypan blue exclusion staining. Similar to the results
of the MTS assay, pre-treatment of cells with CQ
resulted in potentiation of the growth inhibition rate
(60% vs 23% live cells for 5-FU alone and CQ+5FU,
respectively) (Fig. 2B).
CQ increased the formation of Acidic vesicular organelles
(AVOs), and the expression of LC3-II in 5-FU-treated
HT-29 cells
Treatment of HT-29 cells with 5-FU at 5 μMf o r4 8
hours resulted in increased AVOs formation, compared
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induced inhibitory effect of HT-29 cells was time and dose-dependently increased. (B) The proliferative activity of CQ-treated HT-29 cells for 12
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for 48 hours, resulted in potentiation of the inhibitory effect (33% vs. 67% inhibition for 5-FU alone and CQ + 5-FU, respectively). (*, p < 0.05 vs.
control) (B) When cells were treated with CQ at 80 μM for 12 hours prior to exposure to 5-FU at 5 μM for 48 hours, the growth rate reduction
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Page 5 of 11with untreated cells. In addition, the AVOs formation
was also increased by the treatment with the combina-
tion of CQ and 5-FU, compared with cells treated with
5-FU alone (Fig. 3A). Similar results were obtained
with the fluorescence microscopic examination, con-
firming the induction of autophagy. HT-29 cells trea-
ted with CQ and 5-FU displayed great number of red
fluorescence vesicles in the cytoplasm, which represent
AVOs, compared with cells treated with 5-FU alone
(Fig. 3B). Then, to confirm autophagy induction by 5-
F U ,a n dt h ei n h i b i t i o nb yC Q ,t h ee x p r e s s i o no fL C 3 - I I
was investigated in HT-29 cells treated with 5-FU at 5
μM for 24, and 48 hours, by Western blot. The treat-
ment of HT-29 cells with 5-FU alone resulted in
increased accumulation of LC3-II, which was observed
time-dependently, and the effect was potentiated by
CQ-pretreatment (Fig. 4A). The intracellular localiza-
tion of LC3 by immunofluorescence microscopy, after
staining of the cells with fluorescent antibodies to LC3,
revealed an evident punctuate green fluorescence pat-
tern of LC3 in cells treated with 5-FU alone or the
combination of CQ+5-FU, the typical feature of LC3
distribution within autophagosomes (LC3-II). On the
other hand, control untreated cells and cells treated
with CQ alone exhibited only a weak and diffuse cyto-
plasmic staining with LC3-associated green fluores-
cence (Fig 4B). Because CQ inhibits the late step of
autophagy, the accumulation, but not inhibition, of
AVOs and LC3-II were induced.
CQ potentiated the arrest of HT-29 cells to the
G0/G1 phase of the cell cycle, and the
apoptosis induced by 5-FU
The percentage of apoptotic cells (annexin V
+)w e r e
slightly increased by pretreatment with CQ followed by
5-FU (16.5% vs 19.2%; 5-FU alone vs CQ and 5-FU)
(Fig. 5).
Treatment of HT-29 cells with 5-FU alone for 48
hours resulted in increased intra-S cell cycle arrest, as
well as the arrest of the cells to the G0/G1 phase, which
were dose-dependent. Pre-treatment of HT-29 cells with
CQ resulted in strong arrest of cells to the G0/G1 phase
of the cell cycle, compared with cells treated with 5-FU
alone (percentage of cells in G0/G1-phase: 65.1% vs
79.0% for 5-FU alone vs CQ and 5-FU, respectively).
Furthermore, treatment with 5-FU alone for 24 hours
resulted in the inhibition of G2/M progression of HT-29
cells, which was also potentiated by the pretreatment
with CQ (14.7% vs 5.4%; 5-FU alone vs CQ and 5-FU,
respectively) (Fig. 6A). The colony formation was per-
formed to confirm the viability of the cells after the
treatment with 5-FU and/or CQ. Cells were pre-treated
without or with CQ for 12-h followed by 5-FU treat-
ment for 48-h, and then allowed to grow in complete
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FL-3H
c
o
u
n
t
s
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B
Figure 3 CQ increased the formation of Acidic vesicular organelles (AVOs). (A) The formation of AVOs was quantified by flow-cytometry
after acridine orange staining in HT-29 cells treated with 5-FU for 48 h after 12-h pretreatment with CQ. Treatment of HT-29 cells with 5-FU
alone resulted in increased AVOs formation, but the effect was potentiated by CQ-pretreatment. The results are expressed as the mean
fluorescein intensity of acridine orange stained cells. (B) The similar results were obtained with the fluorescence microscopic examination,
confirming the induction of autophagy. HT-29 cells treated with CQ and 5-FU displayed great number of red fluorescence vesicles in the
cytoplasm, which represent AVOs. Because CQ inhibits the late step of autophagy, the accumulation, and not inhibition, of AVOs was induced by
the treatment with CQ.
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Page 6 of 11medium without CQ or 5-FU for 11 days. CQ treatment
alone caused a slight inhibition of the colony-forming
ability of HT-29 cells. Treatment of cells with 5-FU
alone resulted in a significant delay of the colony-form-
ing ability, but at day 11 of culture, approximately 90%
of the cells have formed colonies, suggestive that these
cells were in a dormant state. Furthermore, pre-treat-
ment of cells with CQ at 80 μM for 12 h prior to expo-
sure to 5-FU resulted in potentiation of the inhibitory
effect on the colony-forming ability, which was reduced
to approximately 35% of control untreated cells at day
11 of culture (Fig. 6B).
The G0/G1 arrest of HT-29 cells induced by 5-FU and
potentiated by CQ was dependent on the increase of
p21
Cip1and p27
Kip1, and decrease of CDK2
Treatment of HT-29 cells with 5-FU alone resulted in
decreased expression of p21
Cip1 and p27
Kip1,a n d
simultaneously in increased expression of CDK2, as
detected by Western blot. Pre-treatment of cells with
CQ inhibited the down-regulation of p21
Cip1 and
p27
Kip1 expression induced by 5-FU and, on the other
hand, decreased the expression of CDK2 (Fig. 7). The
expression of cyclin D1 was down-regulated by the
treatment with 5-FU, but not affected by the pre-treat-
ment with CQ.
Discussion
In the present study, we demonstrated the potentiation
of the inhibitory effect of 5-FU on human colon cancer
cells by CQ, the well-known lysosomotropic agent and
the inhibitor of autophagy. Since some studies have sug-
gested the direct cytotoxic effects of CQ on colon can-
cer cells, by inhibiting cell proliferation and inducing
apoptosis [5], in the present study, preliminarily, we
determined the dose of CQ necessary to inhibit
LC3-I
LC3-II
-actin
Control CQ CQ + 5 FU 5 FU
A
B
5-FU CQ pre-treatment + 5-FU
02 4 4 8 0 24 48 hours
1.00 1.09 1.22 1.23 1.39 1.56 Density (LC3-II)
L
C
3
Control CQ CQ + 5-FU 5-FU  B
Figure 4 CQ potentiates the accumulation of LC3-II induced by 5-FU. (A) The expression of LC3-II was quantified by Western blot in HT-29
cells treated with 5-FU alone (left) for 48 h or after 12-h pretreatment with CQ (right). Treatment of HT-29 cells with 5-FU alone resulted in
increased accumulation of LC3-II time-dependently, and the effect was potentiated by CQ-pretreatment. The expression levels of LC3-II are
expressed as the density measured by the Image J software, standardized by the density of b-actin. (B) The intracellular localization of LC3 was
analyzed by immunofluorescence microscopy, by staining the cells with fluorescent antibodies to LC3. Control (untreated) and CQ-treatment
cells exhibited a weak and diffuse cytoplasmic staining with LC3-associated green fluorescence, whereas those treated with 5-FU and CQ pre-
treatment + 5-FU exhibited an evident punctuate green fluorescence pattern of LC3, which is a typical feature of LC3 distribution within
autophagosomes (LC3-II).
6.6 0.9%
control CQ pre-treatment 5-FU CQ + 5-FU
5.9 1.7% 19.2 4.7%
Annexin V-FITC
PI
The percentage of the 
annexin V+ apoptotic 
cells 
16.5 3.9%
Figure 5 CQ potentiates apoptosis of HT-29 cells induced by 5-FU. The population of annexin V
+ apoptotic cells were evaluated by FCM
using annexin V-FITC/PI staining in HT-29 cells after CQ-pretreatment at 80 μM for 12 hours, followed by 5-FU at 5 μM for 48 hours. The
percentage of annexin V
+ apoptotic cells increased by pretreatment with CQ followed by 5-FU (16.5% vs 19.2% for 5-FU alone and CQ+5-FU,
respectively). Values were given as mean ± SD.
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Page 7 of 11autophagy without affecting cell viability. And the treat-
ment of HT-29 cells with the combination of CQ plus
5-FU resulted in potentiation of the inhibitory effect on
the proliferative activity, which was dependent on the
enhancement of the cell cycle arrest to the G0/G1
phase, and also an increase in the percentage of apopto-
tic cells.
Interestingly, in HT-29 cells treated with 5-FU (5 μM)
for 48 hours, the increased formation of AVOs and
increased expression of LC3-II, compared with control
untreated cells, were observed. These are the pathogno-
monic features of autophagy inhibition by CQ. Differing
from the other inhibitors of autophagy, such as 3-MA,
which inhibit autophagy in its early phase, consequently
resulting in inhibition of AVOs formation, CQ inhibits
autophagy in the late phase, when autophagosomes have
already been formed, consequently resulting in accumu-
lation of AVOs, as previously shown by others
[10,18,19]. And the expression of LC3-II changes in par-
allel with AVOs. Therefore, we hypothesized that HT-29
cells induced autophagy as the defense mechanism
against 5-FU, and the inhibition of autophagy by CQ
could be responsible for the potentiation of the anti-
cancer effect of 5-FU. Then, the colony formation assay
24H
control 5-FU CQ + 5-FU
G0/G1; 50.3  0.8%
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S;          15.2  0.9%
G2/M;   12.6  0.4%
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S;          37.3  1.2%
G2/M;   14.7  1.1%
G0/G1; 59.7  0.5%
S;          26.0 0.3%
G2/M;    5.4  0.4%  
A
48H
control U F - 5   +   Q C U F - 5 t n e m t a e r t - e r p   Q C
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G0/G1; 71.7  0.6%
S;          13.3  1.9%
G2/M;  10.4  0.2%
G0/G1; 69.1  3.3%
S;          12.2  0.4%
G2/M;  12.0  0.4%
G0/G1; 65.1  5.3%
S;          20.2  3.8%
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B
control
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Figure 6 CQ potentiates the G0/G1 arrest induced by 5-FU. (A) The analysis of changes in cell cycle was quantified by flow-cytometry after
PI staining in HT-29 cells treated without or with 5-FU for 24, 48 h after 12-h pretreatment without or with CQ. Values were given as mean ±
SD. Treatment of HT-29 cells with 5-FU alone resulted in increased intra-S arrest, but the G1 arrest was potentiated by CQ-pretreatment.
Furthermore, G2/M progression of HT-29 cells was blocked by the treatment with 5-FU alone, and it was potentiated by the 12-h pretreatment
of CQ (*, p < 0.05 vs. control). (B) The colony formation rate was quantified in HT-29 cells treated without or with 5-FU for 48 h after 12-h
pretreatment without or with CQ. Values were given as mean ± SD. Treatment of cells with 5-FU alone resulted in a significant delay in the
colony-forming ability, but at day 11 of culture, approximately 90% of the cells have formed colonies, suggestive that these cells were in a
dormant state. Pre-treatment of cells with CQ prior to exposure to 5-FU resulted in potentiation of the inhibitory effect on the colony forming
ability, which was reduced to approximately 35% of control untreated cells at day 11. CQ alone partially inhibited the colony forming ability of
HT-29, but it was almost completely recovered by day 11.
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Page 8 of 11was conducted to evaluate the behavior of the cells
treated with CQ and/or 5-FU. Interestingly, the colony-
forming ability of cells treated with CQ alone was par-
tially inhibited, suggestive that autophagy is a mechanism
necessary for cell survival under normal conditions. And
more than 95% of the cells had formed colonies at day
11 of culture, confirming that CQ itself has minimal
effect on colon cancer cells. On the other hand, 5-FU
alone significantly inhibited the colony-forming ability of
HT-29. However, at day 11 of culture, about 90% of the
cells had formed colonies, which suggests that the cells
were in a quiescent state, probably dependent on the
induction of autophagy and cell cycle arrest to G0/G1-S-
phase. The combination of CQ and 5-FU resulted in a
more important inhibition of the colony-forming ability,
which was not restored after 11 days in culture. Thus, we
concluded that the autophagic process might be a protec-
tive event against the 5-FU-induced cell cycle arrest of
cells to the G0/G1 phase, and that CQ, by inhibiting the
autophagic process, enhanced the inhibitory effect of
5-FU on HT-29 cells.
In a recent report by Li J et al [15], 3-MA, another
specific inhibitor of autophagy, was shown to enhance
the effect of 5-FU-induced apoptosis in HT-29 cells.
The basic difference between their report and ours is
the inhibitor of autophagy used and the dose of 5-FU
tested. CQ, similar to 3-MA, could efficiently inhibit
autophagy in colon cancer cells, and inhibition of autop-
hagy by CQ potentiated the anti-cancer effect of 5-FU,
similar to 3-MA in this previous study. In the present
study, however, we tested 5-FU at a dose lower than
that in their study, which is a dose quite close to the
physiologically achievable in human plasma [20]. And as
a consequence, whereas they observed strong apoptosis
induction by 5-FU, we found significant inhibition of
the cell cycle to the G0/G1 phase. The relationship
between autophagy and cell cycle is yet poorly known. It
has been reported that rapamycin, an inducer of apopto-
sis and autophagy, leads cells to be arrested to the G0
phase [21], and that, in nutrient-deprived cells, autopha-
gic vacuoles do not accumulate during the meta- and
anaphases of mitosis [22]. In addition, it was reported
that autophagy is closely associated with the advance-
ment of cell cycle, with a preference for the G0/G1 and
S phases [23]. So, it can be speculated that cell cycle
influences autophagic degradation, and the inhibition of
autophagy may lead cells to be arrested to the G0/G1-
phase.
The cell cycle is regulated by cyclins, cyclin-dependent
kinases (CDKs) and CDK inhibitors, such as p21
Cip1 and
p27
Kip1associated proteins [24,25]. The distinct phases
of the cell cycle are controlled by different cyclin/CDK
Cyclin D1
5-FU CQ pre-treatment + 5-FU
02 4 4 8 02 44 8 h o u r s
p27Kip1
Cyclin E
p21Cip1
CDK2
1.00 0.95 0.94 1.03 0.90 0.92
1.00 1.20 1.19 1.10 1.07 1.11
1.00 1.00 0.79 0.94 0.80 0.85
1.00 0.86 0.74 0.93 0.76 0.80
(density)
(density)
(density)
(density)
-actin
CDK4
CDK2
CDK6
1.00 1.40 1.23 1.01 0.98 1.06
1.00 0.80 0.62 0.87 0.72 0.70
1.00 1.18 0.92 1.00 0.88 0.88
(density)
(density)
(density)
Figure 7 Changes in the expression of cyclins, CDKs, CDKs inhibitors. Changes in the expression of cyclins, CDKs, CDKs inhibitors were
quantified by Western blot in HT-29 cells treated with 5-FU for 48 h after 12-h pretreatment with CQ. Treatment of HT-29 cells with 5-FU alone
resulted in decreased expression of cyclin D1, p21
Cip1 and p27
Kip1, time-dependently. In addition, 5-FU treatment resulted in accumulation of
CDK2. Pre-treatment of cells with CQ resulted in inhibition of 5-FU-induced down-regulation of p21
Cip1 and p27
Kip1 expressions and, on the
other hand, decreased the expression of CDK2. The expressions of cyclin E, CDK4 and CDK6 were not affected by 5-FU and/or CQ treatments.
The expression levels of cyclins, CDKs, and CDKs inhibitors are expressed as the density measured by the Image J software, standardized by the
density of b-actin.
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Page 9 of 11complexes, which are activated in response to different
extracellular signals. During G1 phase, the D-type
cyclins (generally cyclin D1)a r ee x p r e s s e di nr e s p o n s e
to mitogenic signals, and by binding to CDK4 and
CDK6, lead to activation of cyclin E/CDK2 and cyclin
A/CDK2 in late G1 and S phase. Cyclin D1 regulates
the physiologic cell proliferation by promoting progres-
sion through key checkpoints in late G1 phase of the
cell cycle. As expected, the expression of cyclin D1 was
down-regulated by the treatment of HT-29 cells with 5-
FU for 24 to 48 h. However, it was not affected by the
pre-treatment with CQ. Other essential regulators of the
cell cycle are the cyclin-dependent kinase (CDK) inhibi-
tors, such as p21
Cip1 and p27
Kip1, which have inhibitory
effects on several CDKs [26,27]. The p21
Cip1 and p27
Kip1
proteins specifically inhibit the complexes formed
between CDK2 and cyclin E, which are required for
entry into S phase from G1 phase [26,27]. Treatment of
HT-29 cells with 5-FU resulted in decreased expressions
of p21
Cip1 and p27
Kip1, and simultaneously in increased
expression of CDK2. The pre-treatment of cells with
CQ inhibited the down-regulation of p21
Cip1 and
p27
Kip1 expressions induced by 5-FU and, on the other
hand, inhibited the up-regulation of the expression of
CDK2. The expressions of cyclin E, CDK4 and CDK6
were not significantly affected by 5-FU and/or CQ treat-
ments. Thus, we speculated that the resulting increased
p21
Cip1 and p27
Kip1, by binding to and consequently
inhibiting the cyclin E/CDK2 complex activity, poten-
tiated the cell cycle arrest in G0/G1 phase, as also
reported by others [28]. Therefore, the up-regulation of
p21
Cip1 and p27
Kip1 expressions in HT-29 cells induced
by CQ, possibly contributed to the potentiation of the
inhibitory effect of 5-FU, by promoting the cell cycle
arrest to G0/G1 phase.
Accumulation of autophagosomes, which is observed
by the treatment with CQ, could either indicate
increased autophagic flux or defective autophagy.
Recently, Wong CH et al. demonstrated the presence of
a reactive oxygen species (ROS)-induced autophagy and
apoptosis pathways in human tumor cell lines and in
primary cells, in which H2O2 was implicated as the pos-
sible upstream stimulus[29]. They demonstrated an
early increase in autophagic flux, but not defective
autophagy, which contributed to cell death execution.
Therefore, it was suggested that the non-classical path-
ways may be invariably associated with cell death, not
working as a cell survival response[29]. The fate of the
cells with accumulated autophagosomes, induced by
CQ, is not definitely reported. However, in the colony-
forming assay, we found that more than 90% of cells,
treated with CQ alone for 12 h, were alive. Thus, it
seems that the autophagosome accumulation induced by
CQ has different implications than that observed in
ROS-induced autophagy.
Recently, an area of growing interest is the potential
contribution of these pro-survival events in promoting
tumor cell resistance to chemotherapy. In this context,
autophagy might play a role as a self-defense mechanism
in 5-FU-treated colon cancer c e l l s ,a n d ,t h u s ,i n h i b i t i o n
of autophagy may be an effective and attractive strategy
to enhance the 5-FU-induced anti-cancer effect in colon
cancer. Indeed, macroautophagy is remarkably up-regu-
lated in colon cancer tissues when compared with the
surrounding non-cancerous tissues, strongly supporting
our hypothesis [30]. Since CQ is already clinically avail-
able, its use in clinical settings of anti-cancer therapy
is feasible, compared with the other autophagy inhibi-
tors, such as 3-MA, which need to have their safety to
human beings confirmed prior to be tested in clinical
trials.
However, it is notable that the long-term effects of
prolonged use of a potent autophagy inhibitor may have
unexpected side effects, as our understanding of the
homeostatic role of autophagy in normal tissues is yet
rudimentary [31]. Other combination therapies for
5-FU, such as Irinotecan, aspirin, proteasome inhibitor,
3-MA are being attempted [15,32-34], and CQ is a new
candidate. In a previous study, we demonstrated that
the pro-apoptotic effect of the chemopreventive agent,
sulforaphane, on human colon cancer cells was poten-
tiated by the pre-treatment of these cells with the speci-
fic inhibitor of autophagy, namely 3-MA [17].
Conclusions
In summary, we clearly demonstrated that the combina-
tion therapy using CQ and 5-FU is an effective and pro-
mising strategy for the treatment of colorectal cancer.
S i n c eC Qi sa l r e a d yi nc l i n i c a lu s ea st h ea n t i m a l a r i a l
drug, as well as an anti-inflammatory drug for the treat-
ment of rheumatoid arthritis, lupus erythematosus and
amoebic hepatitis, its application for the treatment of
colorectal cancer may be feasible without need of phase
I studies.
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